文献速递妇科

全身血液免疫指标对宫颈癌预后价值的系统评价与Meta分析

Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies.
PubMed 文献 · Gynecol Oncol · 2020-10-19

结果显示高NLR、PLR、TLR和CAR均提示预后不良,其中CAR和TLR在晚期FIGO阶段宫颈癌中具有显著预后价值。

要点

  • 高NLR、PLR、TLR和CAR与宫颈癌患者不良预后显著相关。
  • 高TLR和高LMR在FIGO III-IV期宫颈癌中显示显著预后价值。
  • CAR与晚期FIGO阶段及较大肿瘤尺寸患者的不良生存相关。

核心结论

  • 高CAR和TLR以及NLR和PLR在晚期FIGO阶段宫颈癌中具有预后作用。

研究设计与样本

  • 系统检索评估NLR、PLR、LMR、TLR、CAR和SII对宫颈癌患者预后影响的研究。
  • 采用随机效应模型计算风险比或比值比及95%置信区间。

主要发现

  • 高NLR、PLR、TLR和CAR提示宫颈癌患者预后不良,HR分别为2.46、1.88、3.70和3.94,所有P≤0.001。
  • 亚组分析提示最高NLR和PLR在FIGO I-III期宫颈癌放化疗后患者中是更精确的生物标志物。
  • 高TLR和高LMR在晚期FIGO III-IV期宫颈癌中显示显著预后价值,HR分别为4.33和2.032。
  • CAR与晚期FIGO阶段宫颈癌和较大肿瘤尺寸患者的不良生存相关。
  • 根据NLR差异,年轻(43-51岁)宫颈癌患者有碰撞风险增加的趋势;而52-61岁年龄组患者使用PLR合并估计更脆弱。

临床怎么用

  • 可将NLR、PLR、TLR和CAR作为宫颈癌预后评估的参考指标。
  • 在晚期FIGO阶段宫颈癌中,CAR和TLR的预后价值尤为显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the prognostic efficacy of several systemic hemato-immunological indices for the treatment of cervical cancer as well as to determine whether the systemic hemato-immunological indices are associated with an increased risk of cervical collision cancer. METHODS: A systematic search was conducted to identify studies that evaluated the prognostic impact of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), thrombocyte-to-lymphocyte ratio (TLR), C-reactive protein/albumin ratio (CAR), and systemic immune-inflammation index (SII) in cervical cancer patients. The endpoints were overall survival (OS) or progression-free survival (PFS) and clinicopathologic parameters. A meta-analysis using random-effect models was performed to calculate hazard ratios (HRs) or odds ratios with 95% confidence intervals. RESULTS: Twenty-two retrospective cohort studies involving 9558 patients were included. Our results show that high NLR, PLR, TLR, and CAR indicated poor prognosis for patients with cervical cancer (HRs = 2.46, 1.88, 3.70, and 3.94, respectively; all P ≤ 0.001). Subgroup analysis suggested that the highest NLR and PLR were more precise biomarkers in patients who were diagnosed with FIGO stage I-III cervical cancer after treatment with chemo-radiotherapy. High TLR and high LMR displayed significant prognostic value in late-FIGO stage III-IV cervical cancer (HRs = 4.33 and 2.032, respectively). Additionally, CAR was associated with poor survival in patients with advanced-FIGO stage cervical cancer and larger tumor size. According to the difference of NLR, the younger (43-51 years old) cervical cancer patients had a tendency of increased collision risk. However, cervical cancer patients in the 52-61 years age group were more vulnerable than their respective counterparts using the pooled estimate for PLR. CONCLUSION: Our findings support a prognostic role for elevated CAR and TLR besides that of NLR and PLR in advanced-FIGO stage cervical cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Han X, Liu S, Yang G, et al. Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies. Gynecol Oncol. 2020. PMID: 33092868. doi:10.1016/j.ygyno.2020.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。